These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 30622878)
1. Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning. Merk D; Grisoni F; Schaller K; Friedrich L; Schneider G ChemistryOpen; 2019 Jan; 8(1):7-14. PubMed ID: 30622878 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning. Merk D; Grisoni F; Schaller K; Friedrich L; Schneider G ChemistryOpen; 2019 Jan; 8(1):3. PubMed ID: 30622876 [TBL] [Abstract][Full Text] [Related]
3. A New FXR Ligand Chemotype with Agonist/Antagonist Switch. Helmstädter M; Vietor J; Sommer J; Schierle S; Willems S; Kaiser A; Schmidt J; Merk D ACS Med Chem Lett; 2021 Feb; 12(2):267-274. PubMed ID: 33603974 [TBL] [Abstract][Full Text] [Related]
4. Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. Xia J; Wang Z; Huan Y; Xue W; Wang X; Wang Y; Liu Z; Hsieh JH; Zhang L; Wu S; Shen Z; Zhang H; Wang XS J Chem Inf Model; 2020 Mar; 60(3):1202-1214. PubMed ID: 32050066 [TBL] [Abstract][Full Text] [Related]
5. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening. Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339 [TBL] [Abstract][Full Text] [Related]
6. Progress and challenges of selective Farnesoid X Receptor modulation. Massafra V; Pellicciari R; Gioiello A; van Mil SWC Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033 [TBL] [Abstract][Full Text] [Related]
7. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Steri R; Achenbach J; Steinhilber D; Schubert-Zsilavecz M; Proschak E Biochem Pharmacol; 2012 Jun; 83(12):1674-81. PubMed ID: 22414727 [TBL] [Abstract][Full Text] [Related]
9. Discovery of selective farnesoid X receptor agonists for the treatment of hyperlipidemia from traditional Chinese medicine based on virtual screening and in vitro validation. Chen X; Lu F; Luo G; Ren Y; Ma J; Zhang Y J Biomol Struct Dyn; 2020 Sep; 38(15):4461-4470. PubMed ID: 31842697 [TBL] [Abstract][Full Text] [Related]
10. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists. Shen T; Shi A; Wei Y; Luo X; Xi L Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997 [TBL] [Abstract][Full Text] [Related]
11. FXR modulators for enterohepatic and metabolic diseases. Wang H; He Q; Wang G; Xu X; Hao H Expert Opin Ther Pat; 2018 Nov; 28(11):765-782. PubMed ID: 30259754 [TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628 [TBL] [Abstract][Full Text] [Related]
13. Bile acid nuclear receptor FXR and digestive system diseases. Ding L; Yang L; Wang Z; Huang W Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening. Diao Y; Jiang J; Zhang S; Li S; Shan L; Huang J; Zhang W; Li H Front Chem; 2018; 6():140. PubMed ID: 29761098 [TBL] [Abstract][Full Text] [Related]
15. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039 [TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists. Zhao S; Peng W; Li X; Wang L; Yin W; Wang YD; Hou R; Chen WD RSC Adv; 2021 Jan; 11(4):2158-2166. PubMed ID: 35424145 [TBL] [Abstract][Full Text] [Related]
17. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening. Sindhu T; Srinivasan P Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676 [TBL] [Abstract][Full Text] [Related]
18. Natural Products Targeting Liver X Receptors or Farnesoid X Receptor. She J; Gu T; Pang X; Liu Y; Tang L; Zhou X Front Pharmacol; 2021; 12():772435. PubMed ID: 35069197 [TBL] [Abstract][Full Text] [Related]
19. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound. Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277 [TBL] [Abstract][Full Text] [Related]
20. Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking. Giancristofaro A; Barbosa AJM; Ammazzalorso A; Amoia P; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Amoroso R Medchemcomm; 2018 Oct; 9(10):1630-1638. PubMed ID: 30393515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]